var docs;if (!docs) docs =[]; docs["119"]={"11900":"<p><b>Title</b> EPINEPHrine (Systemic) / Bromperidol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromperidol may diminish the therapeutic effect of EPINEPHrine (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of epinephrine and bromperidol.</p> \n<p><b>Discussion</b> The bromperidol product labeling states to avoid the coadministration of bromperidol and epinephrine.<sup>1</sup> The mechanism for this potential interaction is unknown; however, bromperidol use may cause a transient decrease in blood pressure, resulting in the diminished therapeutic effects of epinephrine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Brom (bromperidol) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198800802. Accessed October 27, 2017</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11901":"<p><b>Title</b> Bromperidol / Blood Pressure Lowering Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of bromperidol and blood pressure lowering agents.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The bromperidol prescribing information states to avoid the coadministration of bromperidol and blood pressure lowering agents due to the enhanced and/or diminished effects of these agents when coadministered with bromperidol.<sup>1</sup> The proposed mechanism for this potential interaction is unknown; however, bromperidol use may cause a temporary reduction in blood pressure, resulting in the enhanced hypotensive effects and then rebound effects of blood pressure lowering agents.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Brom (bromperidol) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198800802. Accessed October 27, 2017</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11902":"<p><b>Title</b> Axitinib / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Axitinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Axitinib AUC and maximum serum concentration (Cmax) were reduced by an average of 79% and 71%, respectively, when administered to healthy volunteers (n=40) treated with the strong CYP3A inducer rifampin (600 mg daily for 9 days).<sup>1</sup> <br><br>Axitinib prescribing information recommends avoiding concurrent use with any strong or moderate inducer of CYP3A4.<sup>2</sup> Although axitinib prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, clinical data suggest it is only a weak CYP3A4 inducer.<sup>3</sup><br><br>The likely mechanism for this interaction is induction of the CYP3A-mediated metabolism of axitinib, whose metabolism is primarily via CYP3A.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2010;65(3):563-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19603168\">[PubMed 19603168]</a></p>\n<p>2. Inlyta (axitinib) [prescribing information]. New York, NY: Pfizer Inc; August 2014.</p>\n<p>3. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11903":"<p><b>Title</b> Crizotinib / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Crizotinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The crizotinib (250 mg single dose) AUC and maximum serum concentration were reduced by an average of 82% and 69%, respectively, with concurrent use of the strong CYP3A4 inducer rifampin (600 mg daily for 14 days) in 14 healthy volunteers.<sup>1</sup> <br><br>The crizotinib prescribing information states that concurrent use of crizotinib and strong CYP3A4 inducers should be avoided.<sup>2</sup> Although crizotinib prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, clinical data suggest it is only a weak CYP3A4 inducer.<sup>3</sup><br><br>The likely mechanism of this apparent interaction is induction of CYP3A and an increase in crizotinib metabolism, leading to decreased crizotinib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xu H, O'Gorman M, Tan W, Brega N, Bello A. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. <i>Eur J Clin Pharmacol</i>. 2015;71(12):1441-1449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26381275\">[PubMed 26381275]</a></p>\n<p>2. Xalkori (crizotinib) [prescribing information]. New York, NY: Pfizer Inc; July 2017.</p>\n<p>3. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11904":"<p><b>Title</b> Flibanserin / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Flibanserin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the flibanserin prescribing information, the flibanserin (100 mg single dose) AUC decreased 95% when given after a 7-day course of the strong CYP3A4 inducer rifampin (600 mg daily) in 24 healthy volunteers.<sup>1</sup> Additionally, steady state etravirine (a moderate CYP3A4 inducer) decreased flibanserin exposures by approximately 21%.<sup>1</sup><br><br>The flibanserin prescribing information states that concomitant use of flibanserin and CYP3A4 inducers may substantially reduce flibanserin exposure and effects; use of flibanserin with CYP3A4 inducers is not recommended.<sup>1</sup> Although flibanserin lists rifabutin as an example of a potent CYP3A4 inducer, clinical data suggest it is only a weak CYP3A4 inducer.<sup>2</sup><br><br>The mechanism of this interaction is induction of CYP3A4, the enzyme primarily responsible for flibanserin metabolism, by rifampin, etravirine, or other CYP3A4 inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p>2. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11905":"<p><b>Title</b> Ivacaftor / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Ivacaftor. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study described in ivacaftor prescribing information, coadministration of the strong CYP3A4 inducer rifampin with ivacaftor decreased ivacaftor AUC by approximately 90%.<sup>1,2</sup> <br><br>Ivacaftor prescribing information states that concomitant use of ivacaftor and strong CYP3A4 inducers is not recommended.<sup>1,2</sup> Although ivacaftor prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, clinical data suggest that it is only a weak CYP3A4 inducer.<sup>3</sup><br><br>The proposed primary mechanism of this interaction is rifampin induction of CYP3A4-mediated ivacaftor metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kalydeco (ivacaftor) [prescribing information]. Cambridge, MA: Vertex Pharmaceuticals Inc; July 2017.</p>\n<p>2. Symdeko (tezacaftor and ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Inc; February 2018.</p>\n<p>3. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11906":"<p><b>Title</b> AtorvaSTATin / Esomeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Esomeprazole may enhance the adverse/toxic effect of AtorvaSTATin. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Case Report. A 51-year-old patient stable on atorvastatin (10mg/day for more than 1 year) developed strong evidence of rhabdomyolysis resulting in third-degree heart block after 6 weeks of concomitant therapy with esomeprazole (20mg/day) and 3 doses of clarithromycin (500mg).<sup>1</sup> Related symptoms reportedly began shortly after starting esomeprazole, and heightened after initiating clarithromycin.<br><br>The mechanism of this reported interaction is unclear, but given the reported timeframe, both esomeprazole (longer-term, less severe symptoms) and clarithromycin (acute worsening) were deemed responsible.<sup>1</sup> While the potential for clarithromycin to interact with atorvastatin (and other HMG-CoA reductase inhibitors) is well-recognized (primarily via inhibition of CYP3A-mediated metabolism),<sup>2,3,4</sup> this is the only known report of an interaction between a proton pump inhibitor and an HMG-CoA reductase inhibitor. The authors of the case report attributed the apparent esomeprazole-atorvastatin interaction to inhibition of p-glycoprotein by esomeprazole, leading to impaired atorvastatin efflux. However, data are conflicting regarding both the role of p-glycoprotein in atorvastatin disposition<sup>5,6,7,8</sup> and the ability of proton pump inhibitors (such as esomeprazole) to inhibit p-glycoprotein at therapeutic concentrations.<sup>9,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sipe BE, Jones RJ, and Bokhart GH, “Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction,” <i>Ann Pharmacother</i>, 2003, 37(6):808-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12773066\">[PubMed 12773066]</a></p>\n<p>2. Jacobson TA, “Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered with Cytochrome P450 Inhibitors,” <i>Am J Cardiol</i>, 2004, 94:1140-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15518608\">[PubMed 15518608]</a></p>\n<p>3. Amsden GW, Kuye O,Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42:444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>4. Lee AJ,Maddix DS, “Rhabdomyolysis Secondary to a Drug Interaction between Simvastatin and Clarithromycin,” <i>Ann Pharmacother</i>, 2001, 35:26-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197581\">[PubMed 11197581]</a></p>\n<p>5. Chen C, Lin J, Smolarek T, et al, “P-Glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in Mdr1a/B Knockout and Wild-Type Mice,” <i>Drug Metab Dispos</i>, 2007, 35:1725-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17640956\">[PubMed 17640956]</a></p>\n<p>6. Chen C, Mireles RJ, Campbell SD, et al, “Differential Interaction of 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitors with Abcb1, Abcc2, and Oatp1b1,” <i>Drug Metab Dispos</i>, 2005, 33:537-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15616150\">[PubMed 15616150]</a></p>\n<p>7. Hochman JH, Pudvah N, Qiu J, et al, “Interactions of Human P-Glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin,” <i>Pharm Res</i>, 2004, 21:1686-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15497697\">[PubMed 15497697]</a></p>\n<p>8. Wu X, Whitfield LR,Stewart BH, “Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter,” <i>Pharm Res</i>, 2000, 17:209-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10751037\">[PubMed 10751037]</a></p>\n<p>9. Pauli-Magnus C, Rekersbrink S, Klotz U, et al, “Interaction of Omeprazole, Lansoprazole and Pantoprazole with P-Glycoprotein,” <i>Naunyn Schmiedebergs Arch Pharmacol</i>, 2001, 364:551-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11770010\">[PubMed 11770010]</a></p>\n<p>10. Collett A, Tanianis-Hughes J, Carlson GL, et al, “Comparison of P-Glycoprotein-Mediated Drug-Digoxin Interactions in Caco-2 with Human and Rodent Intestine: Relevance to in Vivo Prediction,” <i>Eur J Pharm Sci</i>, 2005, 26:386-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16153812\">[PubMed 16153812]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11907":"<p><b>Title</b> Rosuvastatin / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Duration</b>: This interaction is likely of greatest potential significance with regular (as opposed to occasional or intermittent) antacid use.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Rosuvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased effects of rosuvastatin (eg cholesterol changes) in patients who consistently take antacids concomitantly. This interaction is likely of little concern when antacid use is intermittent or spaced 2 hours or more after rosuvastatin dosing.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 14 healthy volunteers, coadministration of an antacid (magnesium hydroxide/aluminum hydroxide) and rosuvastatin (40 mg single dose) decreased the rosuvastatin AUC 54%.<sup>1</sup> When the antacid was administered 2 hours after rosuvastatin, the rosuvastatin AUC decreased only 22%.<sup>1</sup><br><br>The rosuvastatin prescribing information states that antacids should be taken at least 2 hours after rosuvastatin administration.<sup>2</sup><br><br>The mechanism of this interaction is unknown, but may be due to the antacid binding or chelating rosuvastatin in the gastrointestinal tract, preventing its absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Martin PD, Schneck DW, Dane AL, Warwick MJ. The effect of a combination antacid preparation containing aluminum hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. <i>Curr Med Res Opin</i>. 2008;24(4):1231-1235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18355422\">[PubMed 18355422]</a></p>\n<p>2. Crestor (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11908":"<p><b>Title</b> Bromperidol / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Bromperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for changes in the therapeutic effects of bromperidol if carbamazepine is initiated/dose is increased or if carbamazepine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 13 schizophrenic patients receiving bromperidol (12 to 24 mg/daily) for 1 to 20 weeks before the addition of carbamazepine (400 mg/daily), carbamazepine (at 4 weeks) decreased plasma concentrations of bromperidol by an average of 37% compared with pre-carbamazepine values.<sup>1</sup> The bromperidol product labeling cautions that a significant decrease in bromperidol plasma concentrations may occur with the coadministration of bromperidol and enzyme-inducing drugs such as carbamazepine.<sup>2</sup> <br><br>The presumed primary mechanism of this interaction is induction of CYP3A4-mediated bromperidol metabolism by carbamazepine, a potent CYP3A4 enzyme inducer.<sup>1,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Otani K, Ishida M, Yasui N, et al. Interaction between carbamazepine and bromperidol. <i>Eur J Clin Pharmacol</i>. 1997;52(3):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9218929\">[PubMed 9218929]</a></p>\n<p>2. Brom (bromperidol) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198800802. Accessed October 27, 2017</p>\n<p>3. Sato S, Someya T, Shioiri O, et al. Involvement of CYP3A4 in the metabolism of bromperidol in vitro. <i>Pharmacol Toxicol</i>. 2000;86(3):145-148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10752674\">[PubMed 10752674]</a></p>\n<p>4. Tateishi T, Watanabe M, Kumai T, et al. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. <i>Life Sci</i>. 2000;67(24):2913-2920. [PubMed PMID: 11133003]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11909":"<p><b>Title</b> LevETIRAcetam / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of LevETIRAcetam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced levetiracetam concentrations or effectiveness.</p> \n<p><b>Discussion</b> Several studies have concluded that concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), such as phenobarbital, results in a small-to-moderate (ie, 7% to 64%) increase in levetiracetam clearance and/or reductions in levetiracetam concentrations that are of uncertain clinical significance.<sup>1,2,3,4,5,6,7,8</sup> Most of these studies examined EIAEDs in aggregate, including most often carbamazepine and phenobarbital. The precise impact of phenobarbital versus other EIAEDs is unclear. The specific mechanism by which phenobarbital or other EIAEDs increase levetiracetam clearance is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aldaz A, Alzueta N, Viteri C. Influence of comedication on levetiracetam Pharmacokinetics. <i>Ther Drug Monit</i>. 2018;40(1):130-134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29210977\">[PubMed 29210977]</a></p>\n<p>2. Stepanova D, Beran RG. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). <i>Seizure</i>. 2014;23(5):371-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24630809\">[PubMed 24630809]</a></p>\n<p>3. Dahlin MG, Wide K, Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. <i>Pediatr Neurol</i>. 2010;43(4):231-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20837299\">[PubMed 20837299]</a></p>\n<p>4. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. <i>Epilepsia</i>. 2007;48(7):1351-1359. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17573925\">[PubMed 17573925]</a></p>\n<p>5. Fountain NB, Conry JA, Rodriguez-Leyva I, et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. <i>Epilepsy Res</i>. 2007;74(1):60-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17270398\">[PubMed 17270398]</a></p>\n<p>6. Contin M, Albani F, Riva R, Baruzzi A. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. <i>Ther Drug Monit</i>. 2004;26(4):375-379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15257066\">[PubMed 15257066]</a></p>\n<p>7. May TW, Rambeck B, Jurgens U. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. <i>Ther Drug Monit</i>. 2003;25(6):690-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14639055\">[PubMed 14639055]</a></p>\n<p>8. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. <i>Epilepsy Res</i>. 2003;53(1-2):47-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12576167\">[PubMed 12576167]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11910":"<p><b>Title</b> LevETIRAcetam / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of LevETIRAcetam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced levetiracetam concentrations or effectiveness.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Several studies have concluded that concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), such as phenytoin, results in a small-to-moderate (ie, 7% to 47%) increase in levetiracetam clearance and/or reductions in levetiracetam concentrations that are of uncertain clinical significance.<sup>1,2,3,4,5,6,7</sup> Most of these studies examined EIAEDs in aggregate, including most often carbamazepine and phenobarbital. The precise impact of phenytoin versus other EIAEDs is unclear. The specific mechanism by which phenytoin or other EIAEDs increase levetiracetam clearance is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. <i>Epilepsy Res</i>. 2003;53(1-2):47-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12576167\">[PubMed 12576167]</a></p>\n<p>2. Stepanova D, Beran RG. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). <i>Seizure</i>. 2014;23(5):371-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24630809\">[PubMed 24630809]</a></p>\n<p>3. Dahlin MG, Wide K, Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. <i>Pediatr Neurol</i>. 2010;43(4):231-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20837299\">[PubMed 20837299]</a></p>\n<p>4. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. <i>Epilepsia</i>. 2007;48(7):1351-1359. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17573925\">[PubMed 17573925]</a></p>\n<p>5. Fountain NB, Conry JA, Rodriguez-Leyva I, et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. <i>Epilepsy Res</i>. 2007;74(1):60-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17270398\">[PubMed 17270398]</a></p>\n<p>6. Contin M, Albani F, Riva R, Baruzzi A. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. <i>Ther Drug Monit</i>. 2004;26(4):375-379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15257066\">[PubMed 15257066]</a></p>\n<p>7. May TW, Rambeck B, Jurgens U. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. <i>Ther Drug Monit</i>. 2003;25(6):690-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14639055\">[PubMed 14639055]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11911":"<p><b>Title</b> LevETIRAcetam / OXcarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of LevETIRAcetam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced levetiracetam concentrations or effectiveness.</p> \n<p><b>Discussion</b> Several studies have concluded that concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including oxcarbazepine, results in a small-to-moderate (ie, 30% to 64%) increase in levetiracetam clearance and/or reductions in levetiracetam concentrations that are of uncertain clinical significance.<sup>1,2,3,4</sup> Most of these studies examined EIAEDs in aggregate, including most often carbamazepine and phenobarbital. The precise impact of oxcarbazepine versus other EIAEDs is unclear. The specific mechanism by which oxcarbazepine or other EIAEDs increase levetiracetam clearance is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aldaz A, Alzueta N, Viteri C. Influence of comedication on levetiracetam Pharmacokinetics. <i>Ther Drug Monit</i>. 2018;40(1):130-134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29210977\">[PubMed 29210977]</a></p>\n<p>2. Dahlin MG, Wide K, Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. <i>Pediatr Neurol</i>. 2010;43(4):231-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20837299\">[PubMed 20837299]</a></p>\n<p>3. Contin M, Albani F, Riva R, Baruzzi A. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. <i>Ther Drug Monit</i>. 2004;26(4):375-379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15257066\">[PubMed 15257066]</a></p>\n<p>4. May TW, Rambeck B, Jurgens U. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. <i>Ther Drug Monit</i>. 2003;25(6):690-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14639055\">[PubMed 14639055]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11912":"<p><b>Title</b> LevETIRAcetam / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of LevETIRAcetam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced levetiracetam concentrations or effectiveness.</p> \n<p><b>Discussion</b> Several studies have concluded that concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), such as phenobarbital (an active metabolite of primidone), results in a small-to-moderate (ie, 7% to 64%) increase in levetiracetam clearance and/or reductions in levetiracetam concentrations that are of uncertain clinical significance.<sup>1,2,3,4,5,6,7,8</sup> Most of these studies examined EIAEDs in aggregate, including most often carbamazepine and phenobarbital. The precise impact of primidone, and how it compares to other EIAEDs is unclear. The specific mechanism by which primidone, phenobarbital, or other EIAEDs increase levetiracetam clearance is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aldaz A, Alzueta N, Viteri C. Influence of comedication on levetiracetam Pharmacokinetics. <i>Ther Drug Monit</i>. 2018;40(1):130-134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29210977\">[PubMed 29210977]</a></p>\n<p>2. Stepanova D, Beran RG. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). <i>Seizure</i>. 2014;23(5):371-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24630809\">[PubMed 24630809]</a></p>\n<p>3. Dahlin MG, Wide K, Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. <i>Pediatr Neurol</i>. 2010;43(4):231-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20837299\">[PubMed 20837299]</a></p>\n<p>4. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. <i>Epilepsia</i>. 2007;48(7):1351-1359. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17573925\">[PubMed 17573925]</a></p>\n<p>5. Fountain NB, Conry JA, Rodriguez-Leyva I, et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. <i>Epilepsy Res</i>. 2007;74(1):60-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17270398\">[PubMed 17270398]</a></p>\n<p>6. Contin M, Albani F, Riva R, Baruzzi A. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. <i>Ther Drug Monit</i>. 2004;26(4):375-379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15257066\">[PubMed 15257066]</a></p>\n<p>7. May TW, Rambeck B, Jurgens U. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. <i>Ther Drug Monit</i>. 2003;25(6):690-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14639055\">[PubMed 14639055]</a></p>\n<p>8. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. <i>Epilepsy Res</i>. 2003;53(1-2):47-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12576167\">[PubMed 12576167]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11913":"<p><b>Title</b> Bromperidol / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Bromperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for changes in the therapeutic effects of bromperidol if itraconazole is initiated/dose is increased or if itraconazole is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 schizophrenic patients receiving bromperidol (12 to 24 mg/daily) for 2 to 49 weeks before the addition of itraconazole (200 mg/daily), itraconazole (at day 7) increased plasma concentrations of bromperidol by an average of 88% compared with pre-itraconazole values.<sup>1</sup> <br><br>The presumed primary mechanism of this interaction is inhibition of CYP3A4-mediated bromperidol metabolism by itraconazole, a potent CYP3A4 inhibitor.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Furukori H, Kondo T, Yasui N, et al. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. <i>Psychopharmacology (Berl)</i>. 1999;145(2):189-192. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10463320\">[PubMed 10463320]</a></p>\n<p>2. Sato S, Someya T, Shioiri O, et al. Involvement of CYP3A4 in the metabolism of bromperidol in vitro. <i>Pharmacol Toxicol</i>. 2000;86(3):145-148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10752674\">[PubMed 10752674]</a></p>\n<p>3. Tateishi T, Watanabe M, Kumai T, et al. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. <i>Life Sci</i>. 2000;67(24):2913-2920. [PubMed PMID: 11133003]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11914":"<p><b>Title</b> Repaglinide / Erythromycin (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The addition of a CYP2C8 inhibitor to this drug combination may substantially increase the magnitude of increase in repaglinide exposure.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of Repaglinide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased hypoglycemic response to repaglinide when used in combination with erythromycin.</p> \n<p><b>Discussion</b> The effect of erythromycin on repaglinide pharmacokinetics has not been evaluated in a clinical study. However, the effect of strong CYP3A4 inhibitors on repaglinide pharmacokinetics has been evaluated in several studies.<sup>1,2,3,4,5</sup> The repaglinide AUC increased 77% when coadministered with telithromycin (800 mg daily for 3 days),<sup>1</sup> 40% when coadministered with clarithromycin (250 mg twice daily for 4 days),<sup>2</sup> 40% when coadministered with itraconazole (100 mg daily),<sup>3,4</sup> and 15% when coadministered with ketoconazole (200 mg daily).<sup>5</sup> In one study the mean serum insulin AUC was increased approximately 50% when repaglinide was combined with clarithromycin.<sup>2</sup> In support of these studies, a case report describes an 80-year old man taking repaglinide for years who experienced 2 episodes of severe hypoglycemia after initiation of clarithromycin therapy.<sup>6</sup><br><br>The suspected mechanism of the above interactions is inhibition of CYP3A4 mediated repaglinide metabolism by strong CYP3A4 inhibitors. However, because CYP3A4 and CYP2C8 are the primary pathways of repaglinide metabolism,<sup>4</sup> the use of repaglinide with both a CYP3A4 and CYP2C8 inhibitor may result in a more significant interaction. Coadministration of the CYP2C8 inhibitor gemfibrozil increased the repaglinide AUC 8.1-fold and the combination of gemfibrozil and itraconazole increased the repaglinide AUC 19.4-fold.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. <i>Clin Pharmacol Ther</i>. 2006;79(3):231-242 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16513447\">[PubMed 16513447]</a></p>\n<p>2. Niemi M, Neuvonen PJ, Kivisto KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. <i>Clin Pharmacol Ther</i>. 2001;70(1):58-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11452245\">[PubMed 11452245]</a></p>\n<p>3. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. <i>Diabetologia</i>. 2003;46(3):347-351. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12687332\">[PubMed 12687332]</a></p>\n<p>4. Prandin (repaglinide) [prescribing information]. Princeton, NJ: Novo Nordisk Pharmaceuticals Inc; 2017.</p>\n<p>5. Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. <i>J Clin Pharmacol</i>. 2003;43(6):649-660. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12817528\">[PubMed 12817528]</a></p>\n<p>6. Khamaisi M, Leitersdorf E. Severe hypoglycemia from clarithromycin-repaglinide drug interaction. <i>Pharmacotherapy</i>. 2008;28(5):682-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18447665\">[PubMed 18447665]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11915":"<p><b>Title</b> Agents With Seizure Threshold Lowering Potential / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> BuPROPion may enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of this combination may significantly increase the risk for seizures. The bupropion labeling recommends considering this possible risk before starting this combination.</p>\n<div>\n <p><b>Agents With Seizure Threshold Lowering Potential Interacting Members</b> Aminophylline, Amisulpride, Amitriptyline, Amoxapine, Amphetamine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Benzphetamine, Blonanserin, Brexpiprazole, Bromperidol, BuPROPion, Caffeine, Cariprazine, ChlorproMAZINE, ClomiPRAMINE, Clothiapine, CloZAPine, Desipramine, Dexmethylphenidate, Dextroamphetamine, Diethylpropion, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Imipramine, Isocarboxazid, Kola Nut, Linezolid, Lisdexamfetamine, Lofepramine, Loxapine, Lurasidone, Melitracen [INT], Meperidine, Methamphetamine, Methotrimeprazine, Methylene Blue, Methylphenidate, Moclobemide, Molindone, Nortriptyline, OLANZapine, Paliperidone, Periciazine, Perphenazine, Phendimetrazine, Phenelzine, Phentermine, Pimozide, Pipamperone [INT], Pipotiazine, Procarbazine, Prochlorperazine, Promazine, Protriptyline, QUEtiapine, Rasagiline, RisperiDONE, Safinamide, Selegiline, Sulpiride, Syrian Rue, Tedizolid, Theophylline, Thioridazine, Thiothixene, TraMADol, Tranylcypromine, Trifluoperazine, Trimipramine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Bupropion use has been associated with a dose-dependent risk for seizures, with a reported incidence of 0.1% at doses up to 300 mg/day and 0.4% at daily doses of 300 mg to 450 mg.<sup>1</sup> The risk is reportedly substantially higher at doses greater than 450 mg/day. Bupropion labeling recommends caution when used with any other drug that may be capable of decreasing the seizure threshold.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wellbutrin XL (bupropion) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11916":"<p><b>Title</b> BuPROPion / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the neuroexcitatory and/or seizure-potentiating effect of BuPROPion. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action may be needed. The bupropion labeling recommends considering this possible risk before starting this combination.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Bupropion use has been associated with a dose-dependent risk for seizures, with a reported incidence of 0.1% at doses up to 300 mg/day and 0.4% at daily doses of 300 mg to 450 mg.<sup>1</sup> The risk is reportedly substantially higher at doses greater than 450 mg/day. Bupropion labeling recommends caution when used with any other drug that may be capable of decreasing the seizure threshold. This label warning specifically includes systemic corticosteroids,<sup>1</sup> even though the evidence in support of these agents having a seizure threshold-lowering effect is limited. One report describes a patient who experienced seizures attributed to prednisone-induced hypocalcemia.<sup>2</sup> However, other supporting data are limited, and several studies describe a role for corticosteroids in the treatment of certain forms of refractory seizures.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wellbutrin XL (bupropion) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; May 2017.</p>\n<p>2. Drug-induced convulsions. Report from Boston Collaborative Drug Surveillance Program. <i>Lancet</i>. 1972;2(7779):677-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4115818\">[PubMed 4115818]</a></p>\n<p>3. Robinson RO. Seizures and steroids. <i>Arch Dis Child</i>. 1985;60(2):94-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2983624\">[PubMed 2983624]</a></p>\n<p>4. Sinclair DB. Prednisone therapy in pediatric epilepsy. <i>Pediatr Neurol</i>. 2003;28(3):194-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12770672\">[PubMed 12770672]</a></p>\n<p>5. Yi ZS, Wu HP, Yu XY, Chen Y, Zhong JM. Efficacy and tolerability of high-dose prednisone in Chinese children with infantile spasms. <i>Brain Dev</i>. 2015;37(1):23-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24657009\">[PubMed 24657009]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11917":"<p><b>Title</b> Anticoagulants / Bromperidol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bromperidol may enhance the adverse/toxic effect of Anticoagulants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for enhanced adverse/toxic effects of anticoagulants when anticoagulants are coadministered with bromperidol.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> The bromperidol prescribing information cautions that patients require careful monitoring during the coadministration of bromperidol and anticoagulants.<sup>1</sup> The reason for this warning is unclear, and the mechanism for this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brom (bromperidol) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198800802. Accessed October 27, 2017</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11918":"<p><b>Title</b> Neuromuscular-Blocking Agents / Bromperidol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bromperidol may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for the prolonged effects of neuromuscular-blocking agents in patients receiving bromperidol and neuromuscular-blocking agents concomitantly.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> The bromperidol prescribing information states that bromperidol use may extend the activity of neuromuscular-blocking agents.<sup>1</sup> The mechanism for and likely clinical significance of this potential interaction are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brom (bromperidol) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198800802. Accessed October 27, 2017</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11919":"<p><b>Title</b> Bromperidol / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Bromperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced therapeutic effects of bromperidol if an antacid is administered concurrently.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The bromperidol prescribing information cautions that antacid use may interfere with bromperidol absorption and reduce its therapeutic effects.<sup>1</sup> There are no data to support this potential interaction, and the mechanism is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brom (bromperidol) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198800802. Accessed October 27, 2017</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11920":"<p><b>Title</b> Bromperidol / Caffeine and Caffeine Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Caffeine and Caffeine Containing Products may decrease the absorption of Bromperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced therapeutic effects of bromperidol if caffeine and caffeine containing products are administered concurrently.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> The bromperidol prescribing information cautions that caffeine use may interfere with bromperidol absorption and reduce its therapeutic effects.<sup>1</sup> There are no data to support this potential interaction and the mechanism is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brom (bromperidol) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198800802. Accessed October 27, 2017</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11921":"<p><b>Title</b> CNS Depressants / Bromperidol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromperidol may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of Bromperidol and CNS Depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The bromperidol prescribing information states that bromperidol should not be used in combination with other CNS depressants due to the risk of oversedation.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Brom (bromperidol) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198800802. Accessed October 27, 2017</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11922":"<p><b>Title</b> Amezinium / Thyroid Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thyroid Products may enhance the stimulatory effect of Amezinium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased effects of sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate) if amezinium and thyroid products are administered concurrently.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> The prescribing information for amezinium cautions that the coadministration of amezinium and thyroid products may increase sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate). The primary mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Risumic (amethinium metilsulfate) tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199800879. Accessed October 30, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11923":"<p><b>Title</b> Amezinium / Antihistamines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihistamines may enhance the stimulatory effect of Amezinium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased effects of sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate) if amezinium and antihistamines are administered concurrently.</p>\n<div>\n <p><b>Antihistamines Interacting Members</b> Acrivastine, Bilastine, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, Clemastine, Cyclizine, Cyproheptadine, Desloratadine, Dexbrompheniramine, Dexchlorpheniramine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Doxylamine, Ebastine, Emedastine (Systemic), Fexofenadine, HydrOXYzine, Ketotifen (Systemic), Levocetirizine, Loratadine, Meclizine, Mequitazine, Olopatadine (Systemic), Oxatomide, Oxomemazine, Pheniramine, Phenyltoloxamine, Pizotifen, Pyrilamine (Systemic), Rupatadine, Thonzylamine, Trimeprazine, Triprolidine</p>\n</div> \n<p><b>Discussion</b> The prescribing information for amezinium cautions that the coadministration of amezinium and antihistamines may increase sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate). The primary mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Risumic (amethinium metilsulfate) tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199800879. Accessed October 30, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11924":"<p><b>Title</b> Amezinium / Atropine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atropine (Systemic) may enhance the stimulatory effect of Amezinium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased effects of sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate) if amezinium and atropine are administered concurrently.</p> \n<p><b>Discussion</b> The prescribing information for amezinium cautions that the coadministration of amezinium and atropine may increase sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate). The primary mechanism of this potential interaction is unknown; however, atropine would be expected to have some additive or synergistic actions resulting from its parasympatholytic actions, likely enhancing the effects of amezinium.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Risumic (amethinium metilsulfate) tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199800879. Accessed October 30, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11925":"<p><b>Title</b> Amezinium / Cortisone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cortisone may enhance the stimulatory effect of Amezinium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased effects of sympathetic nerve stimulation (eg, excitation blood pressure, heart rate) if amezinium and cortisone are administered concurrently.</p> \n<p><b>Discussion</b> The prescribing information for amezinium cautions that the coadministration of amezinium and cortisone may increase sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate). The primary mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Risumic (amethinium metilsulfate) tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199800879. Accessed October 30, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11926":"<p><b>Title</b> Lovastatin / AmLODIPine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> AmLODIPine may increase the serum concentration of Lovastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for signs of HMG-CoA reductase inhibitor toxicity (eg, myositis, rhabdomyolysis) with any use of this combination. An American Heart Association scientific statement recommends limiting the dose of lovastatin to a maximum of 20 mg/day with concurrent use of amlodipine.</p> \n<p><b>Discussion</b> An American Heart Association scientific statement recommends limiting the dose of lovastatin or simvastatin to a maximum of 20 mg/day with concurrent use of amlodipine.<sup>1</sup> This recommendation appears to be based on data with simvastatin, which shows a 77% and 58% increase in the AUC of simvastatin and simvastatin acid, respectively, with concurrent amlodipine (10 mg/day for 10 days).<sup>1,2</sup> No specific data are available with lovastatin, and unlike simvastatin, neither the lovastatin labeling nor the almodipine labeling contain any statement about a potential interaction between amlodipine and lovastatin.<sup>3,4</sup><br><br>The exact mechanism for this potential interaction is uncertain but would likely involve competition for CYP3A as both lovastatin and amlodipine are substrates of this enzyme.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(21):e468-e495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27754879\">[PubMed 27754879]</a></p>\n<p>2. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; February 2015.</p>\n<p>3. Altoprev (lovastatin) [prescribing information]. Zug, Switzerland: Covis Pharma; April 2017.</p>\n<p>4. Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Inc; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11927":"<p><b>Title</b> Lutetium Lu 177 Dotatate / Somatostatin Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Somatostatin Analogs may diminish the therapeutic effect of Lutetium Lu 177 Dotatate. Specifically, the therapeutic effect of Lutetium Lu 177 Dotatate may be diminished if the timing of Somatostatin Analog administration is not carried out as recommended. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> <u>Before initiating lutetium Lu 177 dotatate</u>: Discontinue long-acting somatostatin analogs (eg, long-acting octreotide) at least 4 weeks prior to initiating lutetium Lu 177 dotatate. Administer short-acting octreotide as needed but discontinue it at least 24 hours prior to initiating lutetium Lu 177 dotatate.<br><br><u>During lutetium Lu 177 dotatate treatment</u>: Administer long-acting octreotide 30 mg intramuscularly (IM) 4 to 24 hours after each lutetium Lu 177 dotatate dose. Do not administer long-acting octreotide within 4 weeks of each subsequent lutetium Lu 177 dotatate dose. Short-acting octreotide may be given for symptomatic management during treatment, but must be withheld for at least 24 hours before each lutetium Lu 177 dotatate dose.<br><br><u>Following lutetium Lu 177 dotatate treatment</u>: Continue long-acting octreotide 30 mg IM every 4 weeks after completing lutetium Lu 177 dotatate until disease progression or for up to 18 months following treatment initiation.</p>\n<div>\n <p><b>Somatostatin Analogs Interacting Members</b> Lanreotide, Octreotide, Pasireotide, Somatostatin Acetate</p>\n</div> \n<p><b>Discussion</b> Lutetium Lu 177 dotatate prescribing information states that somatostatin and its analogs competitively bind to somatostatin receptors and may interfere with the efficacy of lutetium Lu 177 dotatate.<sup>1</sup> Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each lutetium Lu 177 dotatate dose.<sup>1</sup> Administer short- and long-acting octreotide during lutetium Lu 177 dotatate treatment as recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lutathera (lutetium Lu 177 dotatate) [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA; January 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11928":"<p><b>Title</b> Warfarin / Revaprazan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Revaprazan may diminish the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased warfarin effects (ie, decreased INR) if combined with revaprazan. Increased warfarin doses may be required.</p> \n<p><b>Discussion</b> In a clinical study of 15 patients stabilized on warfarin therapy, treatment with revaprazan (200 mg daily for at least 7 days) decreased the INR 40% (1.99 vs 1.2; P &lt;0.001).<sup>1</sup> There was a correlation between revaprazan treatment duration and degree of INR shortening suggesting that the longer revaprazan was used, the larger the decrease in INR (R = -0.632; P = 0.012).<sup>1</sup><br><br>The revaprazan prescribing information states that because INR decreases have been seen when revaprazan is coadministered with warfarin, INR should be closely monitored if these agents are combined.<sup>2</sup><br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jung JW, Kang HR, Kwon JW, et al. The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin. <i>Tohoku J Exp Med</i>. 2011;224(4):293-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21799301\">[PubMed 21799301]</a></p>\n<p>2. Revanex (revaprazan) tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200500564. Accessed: June 19, 2017</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11929":"<p><b>Title</b> Reserpine / Amezinium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amezinium may enhance the adverse/toxic effect of Reserpine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased effects of sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate) if amezinium and reserpine are administered concurrently.</p> \n<p><b>Discussion</b> The prescribing information for amezinium cautions that the coadministration of amezinium and reserpine may increase sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate).<sup>1</sup> The primary mechanism of this potential interaction is unknown; however, animal data suggest that amezinium may exert some of its effects through monoamine oxidase inhibition.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Risumic (amethinium metilsulfate) tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199800879. Accessed October 30, 2017.</p>\n<p>2. Steppeler A, Starke K. Selective inhibition by amezinium of intraneuronal monoamine oxidase. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 1980;314(1):13-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442822\">[PubMed 7442822]</a> </p>\n<p>3. Steppeler A, Pfandler R, Hedler L, et al. An analysis of the effects of amezinium on postganglionic sympathetic neurones. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 1980;314(1):1-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442821\">[PubMed 7442821]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11930":"<p><b>Title</b> Clarithromycin / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Clarithromycin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, grapefruit juice (240 mL) coadministered with clarithromycin (500 mg single oral dose) increased the time to maximum serum concentration (Tmax) of clarithromycin 82% and increased the Tmax of the 14-hydroxyclarithromycin (14-OH-C) active metabolite 107%.<sup>1</sup> The AUC, clearance, half-life, and maximum serum concentration of clarithromycin and 14-OH-C were unchanged.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW. Effect of grapefruit juice on clarithromycin pharmacokinetics. <i>Antimicrob Agents Chemother</i>. 1998;42(4):927-929. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9559810\">[PubMed 9559810]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11931":"<p><b>Title</b> Tricyclic Antidepressants / Amezinium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amezinium may enhance the adverse/toxic effect of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased effects of sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate) if amezinium and tricyclic antidepressants are administered concurrently.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> The prescribing information for amezinium cautions that the coadministration of amezinium and tricyclic antidepressants may increase sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate).<sup>1</sup> The primary mechanism of this potential interaction is unknown; however, animal data suggest that amezinium may exert some of its effects through monoamine oxidase inhibition.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Risumic (amethinium metilsulfate) tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199800879. Accessed October 30, 2017.</p>\n<p>2. Steppeler A, Starke K. Selective inhibition by amezinium of intraneuronal monoamine oxidase. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 1980;314(1):13-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442822\">[PubMed 7442822]</a> </p>\n<p>3. Steppeler A, Pfandler R, Hedler L, et al. An analysis of the effects of amezinium on postganglionic sympathetic neurones. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 1980;314(1):1-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442821\">[PubMed 7442821]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11932":"<p><b>Title</b> Droxidopa / Amezinium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amezinium may enhance the adverse/toxic effect of Droxidopa. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased effects of sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate) if amezinium and droxidopa are administered concurrently.</p> \n<p><b>Discussion</b> The prescribing information for amezinium cautions that the coadministration of amezinium and droxidopa may increase sympathetic nerve stimulation (eg, excitation, blood pressure, heart rate).<sup>1</sup> The primary mechanism of this potential interaction is unknown; however, animal data suggest that amezinium may exert some of its effects through monoamine oxidase inhibition.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Risumic (amethinium metilsulfate) tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199800879. Accessed October 30, 2017.</p>\n<p>2. Steppeler A, Starke K. Selective inhibition by amezinium of intraneuronal monoamine oxidase. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 1980;314(1):13-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442822\">[PubMed 7442822]</a> </p>\n<p>3. Steppeler A, Pfandler R, Hedler L, et al. An analysis of the effects of amezinium on postganglionic sympathetic neurones. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 1980;314(1):1-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442821\">[PubMed 7442821]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11933":"<p><b>Title</b> Thiopurine Analogs / Anti-TNF Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of thiopurine analogs and anti-TNF agents may increase the risk for T-cell non-Hodgkin's lymphomas, including hepatosplenic T-cell lymphoma. Consider this possibility when weighing the risks and benefits of combination therapy.</p>\n<div>\n <p><b>Anti-TNF Agents Interacting Members</b> Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, InFLIXimab<br><b>Exceptions</b> Lenalidomide, Pomalidomide, Thalidomide</p>\n <p><b>Thiopurine Analogs Interacting Members</b> AzaTHIOprine, Mercaptopurine, Thioguanine</p>\n</div> \n<p><b>Discussion</b> In one study, an analysis of the FDA Adverse Event Reporting System identified 91 cases of T-cell non-Hodgkin's lymphoma (NHL) in patients who received tumor necrosis factor (TNF) alpha inhibitors and 9 additional cases were found from a MEDLINE search.<sup>1</sup> Of these 100 cases, hepatosplenic T-cell lymphoma (HSTCL) was the most common reported subtype; 68% involved exposure to a TNF-alpha inhibitor and an immunomodulator (azathioprine, 6-mercaptopurine, methotrexate, leflunomide, or cyclosporine). Twenty cases of T-cell NHL were identified in patients receiving thiopurines. The risk of T-cell NHL increased 5-fold with the combination of a TNF-alpha inhibitor and a thiopurine and increased 8-fold with thiopurine use alone. No significant increase in risk was seen with the use of TNF-alpha inhibitors alone. It remains unclear whether the increased risk of T-cell NHL may be attributed to the coadministration of TNF-alpha inhibitors with thiopurines or to thiopurine use alone.<br><br>Prescribing information for several TNF-alpha inhibitors state that postmarketing cases of HSTCL have been reported in patients treated with TNF blockers and almost all of these patients had also received treatment with azathioprine or 6-mercaptopurine.<sup>2,3</sup> The majority of cases occurred in adolescent and young male patients with Crohn's disease or ulcerative colitis.<sup>2,3</sup> It remains uncertain whether the occurrence of HSTCL is related to the use of a TNF blocker or a TNF blocker in combination with other immunosuppressants.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphoma reported to the FDA AERS with tumor necrosis factor-alpha inhibitors: results of the REFURBISH study. <i>Am J Gastroenterol</i>. 2013;108(1):99-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23032984\">[PubMed 23032984]</a></p>\n<p>2. Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2017.</p>\n<p>3. Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11951":"<p><b>Title</b> Obeticholic Acid / BSEP/ABCB11 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> BSEP/ABCB11 Inhibitors may increase serum concentrations of the active metabolite(s) of Obeticholic Acid. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of obeticholic acid and bile salt efflux pump (BSEP) inhibitors if possible. If concomitant therapy is necessary, monitor patients for increased obeticholic acid toxicities and effects (eg, elevated liver transaminases, elevated bilirubin)</p>\n<div>\n <p><b>BSEP/ABCB11 Inhibitors Interacting Members</b> CycloSPORINE (Systemic), SORAfenib, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Obeticholic acid prescribing information states that in vitro, the taurine conjugate of obeticholic acid is a substrate of the bile salt efflux pump (BSEP).<sup>1</sup> Use of medications that inhibit BSEP may result in accumulation of conjugated bile salts and the taurine conjugate of obeticholic acid resulting in clinical symptoms and toxicities.<sup>1</sup> No clinical studies have evaluated the effect of BSEP inhibitors on obeticholic acid exposure or outcomes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ocalvia (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; January 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11952":"<p><b>Title</b> Cyclophosphamide / Ondansetron</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ondansetron may decrease the serum concentration of Cyclophosphamide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a retrospective study of bone marrow transplant recipients receiving high-dose cyclophosphamide, cisplatin, and carmustine, 23 patients who received ondansetron were compared with 129 patients who received prochlorperazine.<sup>1</sup> The cyclophosphamide AUC was 15% lower and the cisplatin AUC was 19% lower in patients who received ondansetron compared with those who received prochlorperazine.<sup>1</sup> The AUC of carmustine was not significantly different between groups.<sup>1</sup> In another retrospective analysis of breast cancer patients receiving high-dose cyclophosphamide, cisplatin and carmustine, 54 patients who received ondansetron were compared with 75 matched historical controls who had received prochlorperazine.<sup>2</sup> The cyclophosphamide AUC was 17% lower and the cisplatin AUC was 10% higher in patients who received ondansetron compared with those who received prochlorperazine.<sup>2</sup> The AUC of carmustine was not different between groups.<sup>2</sup><br><br>The clinical significance and mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. <i>Bone Marrow Transplant</i>. 1999;24(1):1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10435726\">[PubMed 10435726]</a></p>\n<p>2. Gilbert CJ, Petros WP, Vredenburgh J, et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. <i>Cancer Chemother Pharmacol</i>. 1998;42(6):497-503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9788577\">[PubMed 9788577]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11953":"<p><b>Title</b> CISplatin / Ondansetron</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ondansetron may increase the serum concentration of CISplatin. Ondansetron may decrease the serum concentration of CISplatin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a retrospective study of bone marrow transplant recipients receiving high-dose cyclophosphamide, cisplatin, and carmustine, 23 patients who received ondansetron were compared with 129 patients who received prochlorperazine.<sup>1</sup> The cyclophosphamide AUC was 15% lower and the cisplatin AUC was 19% lower in patients who received ondansetron compared with those who received prochlorperazine.<sup>1</sup> The AUC of carmustine was not significantly different between groups.<sup>1</sup> In another retrospective analysis of breast cancer patients receiving high-dose cyclophosphamide, cisplatin and carmustine, 54 patients who received ondansetron were compared with 75 matched historical controls who had received prochlorperazine.<sup>2</sup> The cyclophosphamide AUC was 17% lower and the cisplatin AUC was 10% higher in patients who received ondansetron compared with those who received prochlorperazine.<sup>2</sup> The AUC of carmustine was not different between groups.<sup>2</sup><br><br>The clinical significance and mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. <i>Bone Marrow Transplant</i>. 1999;24(1):1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10435726\">[PubMed 10435726]</a></p>\n<p>2. Gilbert CJ, Petros WP, Vredenburgh J, et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. <i>Cancer Chemother Pharmacol</i>. 1998;42(6):497-503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9788577\">[PubMed 9788577]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11954":"<p><b>Title</b> AzaTHIOprine / InFLIXimab</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> InFLIXimab may enhance the adverse/toxic effect of AzaTHIOprine. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. InFLIXimab may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of thiopurine analogs (ie, azathioprine) and anti-TNF agents (ie, infliximab) may increase the risk for T-cell non-Hodgkin's lymphomas, including hepatosplenic T-cell lymphoma. Consider this possibility when weighing the risks and benefits of combination therapy. Additionally, monitor for increases in known azathioprine toxicities (eg, leukopenia) if combined with infliximab.</p> \n<p><b>Discussion</b> In one study, an analysis of the FDA Adverse Event Reporting System identified 91 cases of T-cell non-Hodgkin's lymphoma (NHL) in patients who received tumor necrosis factor (TNF) alpha inhibitors and 9 additional cases were found from a MEDLINE search.<sup>1</sup> Of these 100 cases, hepatosplenic T-cell lymphoma (HSTCL) was the most common reported subtype; 68% involved exposure to a TNF-alpha inhibitor and an immunomodulator (azathioprine, 6-mercaptopurine, methotrexate, leflunomide, or cyclosporine). Twenty cases of T-cell NHL were identified in patients receiving thiopurines. The risk of T-cell NHL increased 5-fold with the combination of a TNF-alpha inhibitor and a thiopurine and increased 8-fold with thiopurine use alone. No significant increase in risk was seen with the use of TNF-alpha inhibitors alone. It remains unclear whether the increased risk of T-cell NHL may be attributed to the coadministration of TNF-alpha inhibitors with thiopurines or to thiopurine use alone.<br><br>In addition to the risk for lymphoma with this drug combination, a pharmacokinetic study conducted in 32 patients with Crohn's disease on stable doses of azathioprine found that 1 to 3 weeks after an infliximab infusion, concentrations of 6-tioguanine nucleotide (the active metabolite of azathioprine) increased 60%.<sup>2</sup> During this time, a significant decrease in leucocyte count and an increase in mean corpuscular volume were observed.<sup>2</sup> Concentrations of 6-tioguanine nucleotide and laboratory values returned to baseline 3 months after infliximab infusion.<sup>2</sup><br><br>Prescribing information for infliximab states that postmarketing cases of HSTCL have been reported in patients treated with TNF blockers and almost all of these patients had also received treatment with azathioprine or 6-mercaptopurine.<sup>3</sup> The majority of cases occurred in adolescent and young male patients with Crohn's disease or ulcerative colitis.<sup>3</sup> It remains uncertain whether the occurrence of HSTCL is related to the use of a TNF blocker or a TNF blocker in combination with other immunosuppressants.<sup>3</sup> <br><br>The mechanism for an increased risk of lymphoma is unknown, but likely relates to additive immunosuppressant activity with this combination. The mechanism by which infliximab may increase concentrations of the active metabolite of azathioprine is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphoma reported to the FDA AERS with tumor necrosis factor-alpha inhibitors: results of the REFURBISH study. <i>Am J Gastroenterol</i>. 2013;108(1):99-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23032984\">[PubMed 23032984]</a></p>\n<p>2. Roblin X, Serre-Debeauvais F, Phelip JM, Bessard G, Bonaz B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. <i>Aliment Pharmacol Ther</i>. 2003;18(9):917-925. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616155\">[PubMed 14616155]</a></p>\n<p>3. Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11955":"<p><b>Title</b> Ritodrine / Corticosteroids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms (eg, fluid retention, tachycardia, tachypnea, headaches, fatigue) of clinically significant interactions related to cardiopulmonary adverse effects and hyperglycemia. Monitor laboratory measurements as appropriate (eg, electrolytes, blood pressure, chest x-ray, ECG changes, fasting blood glucose).</p>\n<div>\n <p><b>Corticosteroids Interacting Members</b> Alclometasone, Amcinonide, Beclomethasone (Nasal), Beclomethasone (Oral Inhalation), Beclomethasone (Topical), Betamethasone (Nasal), Betamethasone (Ophthalmic), Betamethasone (Systemic), Betamethasone (Topical), Budesonide (Nasal), Budesonide (Oral Inhalation), Budesonide (Systemic), Budesonide (Topical), Ciclesonide (Nasal), Ciclesonide (Oral Inhalation), Clobetasol, Clobetasone, Clocortolone, Corticotropin, Cortisone, Deflazacort, Desonide, Desoximetasone, Dexamethasone (Ophthalmic), Dexamethasone (Systemic), Diflorasone, Diflucortolone, Difluprednate, Fludrocortisone, Flunisolide (Nasal), Flunisolide (Oral Inhalation), Fluocinolone (Ophthalmic), Fluocinolone (Topical), Fluocinonide, Fluorometholone, Flurandrenolide, Fluticasone (Nasal), Fluticasone (Oral Inhalation), Fluticasone (Topical), Halcinonide, Halobetasol, Hydrocortisone (Ophthalmic), Hydrocortisone (Systemic), Hydrocortisone (Topical), Loteprednol, Medrysone, MethylPREDNISolone, Mometasone (Nasal), Mometasone (Oral Inhalation), Mometasone (Topical), Prednicarbate, PrednisoLONE (Ophthalmic), PrednisoLONE (Systemic), PrednisoLONE (Topical), PredniSONE, Rimexolone, Tixocortol Pivalate, Triamcinolone (Nasal), Triamcinolone (Ophthalmic), Triamcinolone (Systemic), Triamcinolone (Topical)</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 5 pregnant women, heart rate, respiratory rate, systolic blood pressure, and oxygen requirements increased significantly when intravenous (IV) ritodrine (0.9 to 7.2 mcg/kg/min) was administered with betamethasone (12 mg IV 30 min before ritodrine) compared with ritodrine alone.<sup>1</sup><br><br>Five cases (3 with ritodrine, 2 with isoxsuprine with either hydrocortisone or betamethasone) presented with symptoms of dyspnea, shortness of breath, and productive cough with blood-tinged sputum. Pulmonary edema and heart failure diagnoses were confirmed with chest x-ray and physical examination. Although maternal symptoms resolved in all cases, there was 1 stillbirth and 1 neonatal death.<sup>2,3,4</sup><br><br>There was also a case of acute respiratory distress syndrome as a complication following ritodrine (150 mg initiated at 20 mL/h then 40mL/h) and betamethasone (12 mg intramuscularly) coadministration. Twelve hours post-delivery, the patient experienced tachypnea, cough, and fever. Chest x-ray revealed crackles at the right base of the lung; she was subsequently intubated, requiring mechanical ventilation and PEEP therapy for 6 days. Three weeks following her initial onset of symptoms, she was asymptomatic with pulmonary function tests almost at baseline.<sup>5</sup><br><br>Effects on blood glucose were also observed in a retrospective case-control study, where insulin requirements were 30 units/day higher on average in diabetic patients (N=9) and fasting blood glucose increased by 40 mg/dL in non-diabetic patients (N=45) with ritodrine and betamethasone coadministration. <sup>6</sup><br><br>The cardiopulmonary effects of tocolytics are thought to be likely due to their resemblance to other sympathomimetics, such as epinephrine.<sup>2</sup> An upregulation of beta receptors observed with glucocorticoids may also explain these potentiated effects of tocolytics.<sup>1,7</sup><br><br>Although corticosteroids are routinely used to improve fetal lung maturation in pregnancy, maternal adverse effects, such as pulmonary edema and heart failure may occur; therefore, monitoring for clinical signs and symptoms of fluid retention and decline in pulmonary and cardiovascular function is recommended. Prescribing information also recommends monitoring for hyperglycemia and hypokalemia when corticosteroids and ritodrine are coadministered.<sup>8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Spatling L, Staisch KJ, Huch R, Huch A. Effect of ritodrine and betamethasone on metabolism, respiration, and circulation. <i>Am J Perinatol.</i> 1986;3(1):41-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3942613\">[PubMed 3942613]</a></p>\n<p>2. Semchyshyn S, Zuspan FP, O'Shaughnessy R. Pulmonary edema associated with the use of hydrocortisone and a tocolytic agent for the management of premature labor. <i>J Reprod Med.</i> 1983;28(1):47-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6834348\">[PubMed 6834348]</a></p>\n<p>3. Elliot HR, Abdulla U, Hayes PJ. Pulmonary oedema associated with ritodrine infusion and betamethasone administration premature labour. <i>Br Med J.</i> 1978;2(6140):799-800. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=698738\">[PubMed 698738]</a></p>\n<p>4. Tinga DJ, Aarnoudse JG. Post-partum pulmonary oedema associated with preventative therapy for premature labour. <i>Lancet.</i> 1979;1(8124):1026. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=86735\">[PubMed 86735]</a></p>\n<p>5. Bowen RE, Dedhia HV, Beatty J, Schiebel F, Koss W, Granados J. ARDS associated with the use of sympathomimetics and glucocorticoids for the treatment of premature labor. <i>Crit Care Med.</i> 1983;11(8):671-672. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6872557\">[PubMed 6872557]</a></p>\n<p>6. Ogawa M, Matsuda Y, Kobayashi A, et al. Ritodrine should be carefully administered during antenatal glucocorticoid therapy even in nondiabetic pregnancies. <i>ISRN Obstet Gynecol.</i> 2013;2013;102735. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23533796\">[PubMed 23533796]</a></p>\n<p>7. Fraser CM, Venter JC. The synthesis of beta-adrenergic receptors in cultured human lung cells: induction by glucocorticoids. <i>Biochem Biophys Res Comm.</i> 1980;94(1):390-397. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6248064\">[PubMed 6248064]</a></p>\n<p>8. Labo Paju (ritodrine hydrochloride) (ex: Yutoparinj) injection [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198200072 Accessed October 26, 2017.</p>\n<p>9. Lavopar (ritodrine hydrochloride) capsules [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200200250 Accessed December 5, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11956":"<p><b>Title</b> Ritodrine / Atropine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atropine (Systemic) may enhance the adverse/toxic effect of Ritodrine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor signs and symptoms of potentiated cardiovascular effects (eg, tachycardia, hypertension) with concomitant use of ritodrine and atropine.</p> \n<p><b>Discussion</b> In a study of 47 patients experiencing fetal distress, 24 patients received ritodrine 6 mg intravenously (IV) over 3 minutes prior to caesarean section.<sup>1</sup> Two mothers who received atropine in addition to ritodrine experienced severe tachycardia (190 beats/min for 15 minutes and not less than 100 beats/min for 1 hour) and marked systolic hypertension (150 to 190 mmHg). <sup>1</sup> Current prescribing information warns of cardiovascular effects from coadministration of atropine and ritodrine. <sup>2</sup> Therefore, close monitoring cardiovascular parameters, such as heart rate and blood pressure, is warranted if this combination of agents is used.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sheybany S, Murphy JF, Evans D, Newcome RG, Pearson JF. Ritodrine in the management of fetal distress. <i> Br J Obstet Gynaecol.</i> 1982;89(9):723-726. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7115635\">[PubMed 7115635]</a></p>\n<p>2. Labo Paju (ritodrine hydrochloride) (ex: Yutoparinj) injection [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198200072 Accessed October 26 2017.</p>\n<p>3. Lavopar (ritodrine hydrochloride) capsules [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200200250 Accessed December 5, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11957":"<p><b>Title</b> Cefpirome / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may enhance the nephrotoxic effect of Cefpirome. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cefpirome together with a loop diuretic, using particular caution and close monitoring with higher doses of loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> The prescribing information for cefpirome cautions that concurrent use with loop diuretics may increase the risk for renal dysfunction.<sup>1</sup> Loop diuretics have been associated with nephrotoxicity, and a prior study found that moderate doses of furosemide were associated with prolonged elimination of the cephalosporin antibiotic cephaloridine.<sup>2</sup> The authors of that report concluded that moderate or higher doses of loop diuretics could increase the nephrotoxicity of cephalosporin antibiotics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hancerom (cefpirome) injection [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200605485. Accessed: October 26, 2017.</p>\n<p>2. Norrby R, Stenqvist K, Elgefors B. Interaction between cephaloridine and furosemide in man. <i>Scand J Infect Dis</i>. 1976;8(3):209-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=968459\">[PubMed 968459]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11958":"<p><b>Title</b> Magnesium Sulfate / Ritodrine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritodrine may enhance the adverse/toxic effect of Magnesium Sulfate. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor signs and symptoms for possible cardiac dysrhythmias, musculoskeletal adverse effects (eg, rhabdomyolysis), and renal dysfunction. Laboratory measurements (eg, ECG, creatine kinase, serum creatinine) should be monitored, as appropriate.</p> \n<p><b>Discussion</b> Significant chest pain and ECG changes were observed in a clinical study of pregnant women (N=41) who received ritodrine (initiated at 50 mcg/min up to 350 mcg/min) plus magnesium sulfate (first hour 8.4 g, second hour 4.8 g then 2.4 g/hour) versus ritodrine alone. <sup>1</sup> Eleven out of 24 patients receiving ritodrine plus magnesium sulfate experienced adverse effects, whereas one 1 out 17 patients receiving ritodrine alone did not experience adverse effects. ECG changes illustrated ST segment depression in 70% of patients with chest pain.<sup>1</sup><br><br>Other adverse effects such as elevated creatinine kinase (CK) levels were demonstrated in a retrospective cohort of 27 patients (N=10 received IV ritodrine 50 mcg/min up to 200 mcg/minute; N=17 received ritodrine and IV magnesium sulfate 4 g then 1 to 2 g/hour).<sup>2</sup> Patients with elevated CK levels (up to 215 units/L) received significantly higher doses of both drugs. Muscle pain nor renal dysfunction were recorded in these patients.<sup>2</sup><br><br>Following 5 weeks of ritodrine and magnesium sulfate combined therapy in the case of a twin pregnancy, CK levels were elevated (322 units/L) along with liver enzymes, AST and ALT (86 units/L and 102 units/L), respectively.<sup>3</sup> CK level increased to 1,167 units/L accompanied with muscle pain. Ritodrine was discontinued with a diagnosis of drug-induced rhabdomyolysis. Once ritodrine was removed, all symptoms resolved and the twins were successfully delivered via caesarian section.<sup>3</sup><br><br>Maternal and neonatal effects of ritodrine and magnesium sulfate coadministration were also documented in another a case report where CK levels in the mother increased to 746 units/L and high levels of serum creatinine greater than 0.7 mg/dL as well as high serum CK developed in one twin.<sup>4</sup> Renal function and CK levels in the other twin were within normal values.<sup>4</sup><br><br>In contrast, a clinical study (N=74) demonstrated maternal and fetal adverse effects did not significantly differ in women treated with ritodrine (50 mcg/min IV up to maximum 350 mcg/min) and magnesium sulfate (4 g IV bolus then 2 to 3 g/hpur as needed) (N=38) versus ritodrine alone (N=36).<sup>5</sup><br><br>Use of magnesium sulfate and ritodrine in combination may routinely be used to enhance tocolytic activity in preterm labor, but clinical data surrounding the potential for adverse effects with magnesium sulfate and ritodrine coadministration are conflicting. There is, however, enough clinical evidence in the primary literature demonstrating the existence of adverse effects when these agents are used in combination. Prescribing information indicates CK levels may increase with combined ritodrine and magnesium sulfate; therefore, CK levels and renal function tests should be monitored.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ferguson JE 2nd, Hensleigh PA, Kredenster D. Adjunctive use of magnesium sulfate with ritodrine for preterm labor tocolysis. <i>Am J Obstet Gynecol</i>. 1984;148(2):166-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6362416\">[PubMed 6362416]</a></p>\n<p>2. Matsuda Y, Nagayoshi Y, Kirihara N. Evaluation of creatine kinase level during long-term tocolysis. <i>J Perinat Med</i>. 2002;30(6):476-479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12530103\">[PubMed 12530103]</a></p>\n<p>3. Matsuda Y, Nagayoshi Y, Kirihara N. Rhabdomyolysis during prolonged intravenous tocolytic therapy. <i>J Perinat Med</i>. 2002;30(6)514-516. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12530109\">[PubMed 12530109]</a></p>\n<p>4. Ohta N, Tsukahara H, Yamashita N, et al. Infantile renal dysfunction associated with intrauterine exposure to ritodrine and magnesium sulfate. <i>Nephron</i>. 2002;91(2):352-353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12053081\">[PubMed 12053081]</a></p>\n<p>5. Hatjis CG, Swain M, Nelson LH, Meis PJ, Ernest JM. Efficacy of combined administration of magnesium sulfate and ritodrine in the treatment of premature labor. <i>Obstet Gynecol</i>. 1987;69(3 pt 1):317-322. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3822278\">[PubMed 3822278]</a></p>\n<p>6. Labo Paju (ritodrine hydrochloride) (ex: Yutoparinj.) injection [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198200072 Accessed October 26 2017.</p>\n<p>7. Lavopar (ritodrine hydrochloride) capsules [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200200250 Accessed December 5, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11959":"<p><b>Title</b> Inhalational Anesthetics / Ritodrine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritodrine may enhance the adverse/toxic effect of Inhalational Anesthetics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of cardiovascular adverse effects (eg, elevated blood pressure, tachycardia, cardiac dysrhythmias) when ritodrine and inhalational anesthetics are coadministered. Ritodrine should be discontinued 6 hours prior to the start of the anesthetic. Cyclopropane is not recommended in patients receiving ritodrine.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Significantly elevated systolic blood pressures (155 mm Hg to 185 mm Hg) were reported in pregnant patients who received ritodrine and cyclopropane (N=6) versus cyclopropane alone (N=37).<sup>1</sup> In 2 patients in the ritodrine and cyclopropane group, cardiac dysrhythmias were also observed.<sup>1</sup><br><br>A case report using another beta-2 agonist, orciprenaline, also illustrated marked increases in heart rate (160 beats per minute) but, in contrast, decreases in systolic blood pressures (80 to 90 mm Hg) with halothane.<sup>2</sup><br><br>Prescribing information warns of potentiated effects of ritodrine, such as cardiovascular adverse effects (eg, ventricular arrhythmias), uterine contractility and bleeding, when an anesthetic is coadministered. Because of the label warnings and adverse effects reported in case reports, the coadministration of ritodrine and anesthetics should be monitored.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Johannsen G. Ritodrine and cyclopropane interaction. <i>Anaesthesia</i>. 1980:35(1):84-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7396133\">[PubMed 7396133]</a></p>\n<p>2. Knight RJ. Labour retarded with beta-agonist drugs: A therapeutic problem in emergency anaesthesia. <i>Anaesthesia</i>. 1977;32(7):639-641. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=900438\">[PubMed 900438]</a></p>\n<p>3. Labo Paju (ritodrine hydrochloride) (ex: Yutoparinj.) injection [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198200072 Accessed October 26 2017.</p>\n<p>4. Lavopar (ritodrine hydrochloride) capsules [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200200250 Accessed December 5, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11960":"<p><b>Title</b> Antidiabetic Agents / Ritodrine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritodrine may diminish the therapeutic effect of Antidiabetic Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor signs and symptoms (eg, hyperglycemia, acidosis, ketonuria) of potential diabetic ketoacidosis in patients receiving antidiabetic agents. Adjust tocolytic or antidiabetic therapy accordingly.</p>\n<div>\n <p><b>Antidiabetic Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, ChlorproPAMIDE, Dapagliflozin, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, MetFORMIN, Miglitol, Mitiglinide, Nateglinide, Pioglitazone, Pramlintide, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> One case report describes a woman who was stabilized on oral ritodrine (10 mg daily) and insulin who experienced symptoms of dyspnea and drowsiness with the administration of an IV infusion of ritodrine (18 mg/hour).<sup>1</sup> Subsequently, the patient was hyperglycemic (21.5 mmol/L) and acidotic (pH 6.97) with ketonuria. Her blood glucose was erratically controlled with IM insulin with blood glucose values ranging from approximately 2 mmol/L to 30 mmol/L. When ritodrine was discontinued, the patient’s symptoms resolved but fetal heart sounds were undetectable.<sup>1</sup><br><br>Two other cases reported elevated blood glucose levels of 200 mg/dL (11.1 mmol/L) in one case and 155 additional units of insulin were used to control blood glucose in the other case.<sup>2</sup> Ketonuria, glycosuria, and acidosis were also reported with IV ritodrine (up to 21 mg/hour) coadministration. When ritodrine was discontinued, symptoms resolved in both cases and infants were delivered with minimal complications.<sup>2</sup><br><br>Due to significant adverse effects observed in diabetic pregnant women when they received IV ritodrine, prescribing information indicates dosage adjustments of the patient's antidiabetic therapy may be necessary with this combination.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schilthuis MS, Aarnoudse JG. Fetal death associated with severe ritodrine induced ketoacidosis. <i>Lancet</i>. 1980;1(8178):1145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6103486\">[PubMed 6103486]</a></p>\n<p>2. Mordes D, Kreutner K Metzger W, Colwell JA. Dangers of intravenous ritodrine in diabetic patients. <i>JAMA</i>. 1982;248(8):973-975. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6808166\">[PubMed 6808166]</a></p>\n<p>3. Labo Paju (ritodrine hydrochloride) (ex: Yutoparinj.) injection [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198200072 Accessed October 26 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11962":"<p><b>Title</b> Tezacaftor / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tezacaftor. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> When tezacaftor/ivacaftor is combined with strong CYP3A4 inhibitors, dose adjustment is required. Tezacaftor/ivacaftor (100 mg/150 mg) should be administered in the morning, twice a week, approximately 3 to 4 days apart. No evening doses of ivacaftor (150 mg) alone should be administered.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the tezacaftor/ivacaftor prescribing information, itraconazole (200 mg twice daily for 2 doses, followed by 200 mg daily) coadministered with tezacaftor/ivacaftor (25 mg/50 mg once daily) increased the tezacaftor AUC and maximum serum concentration 4.0-fold and 2.8-fold, respectively.<sup>1</sup><br><br>The tezacaftor/ivacaftor prescribing information states that tezacaftor/ivacaftor dose adjustments are required when combined with strong CYP3A4 inhibitors.<sup>1</sup> Tezacaftor/ivacaftor (100 mg/150 mg) should be administered in the morning, twice a week, approximately 3 to 4 days apart. No evening doses of ivacaftor (150 mg) alone should be administered.<sup>1</sup><br><br>The mechanism of this interaction is likely due to itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for the metabolism of tezacaftor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Symdeko (tezacaftor and ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11963":"<p><b>Title</b> Tezacaftor / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When tezacaftor/ivacaftor is combined with moderate CYP3A4 inhibitors, dose adjustment is required. Tezacaftor/ivacaftor (100 mg/150 mg) should be administered in the morning, every other day. Ivacaftor (150 mg) alone should be administered in the evening, every other day, on alternate days from tezacaftor/ivacaftor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the tezacaftor/ivacaftor prescribing information, the strong CYP3A4 inhibitor itraconazole (200 mg twice daily for 2 doses, followed by 200 mg daily) coadministered with tezacaftor/ivacaftor (25 mg/50 mg once daily) increased the tezacaftor AUC and maximum serum concentration 4.0-fold and 2.8-fold, respectively.<sup>1</sup> Simulation suggested that coadministration with fluconazole, a moderate CYP3A inhibitor, may increase tezacaftor AUC by approximately 2.0-fold.<sup>1</sup><br><br>The tezacaftor/ivacaftor prescribing information states that tezacaftor/ivacaftor dose adjustments are required when combined with moderate CYP3A4 inhibitors.<sup>1</sup> Tezacaftor/ivacaftor (100 mg/150 mg) should be administered in the morning, every other day. Ivacaftor (150 mg) alone should be administered in the evening, every other day, on alternate days from tezacaftor/ivacaftor.<sup>1</sup><br><br>The mechanism of this interaction is likely due to itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for the metabolism of tezacaftor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Symdeko (tezacaftor and ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11964":"<p><b>Title</b> Apalutamide / CYP2C8 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Strong) may increase the serum concentration of Apalutamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased apalutamide toxicities when combined with strong CYP2C8 inhibitors. Apalutamide dose reductions may be required (to 180 mg or 120 mg daily) if toxicities occur.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Strong) Interacting Members</b> Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the apalutamide prescribing information, gemfibrozil increased the apalutamide (240 mg single dose) AUC 68% and decreased the maximum serum concentration (Cmax) 21%.<sup>1</sup> Gemfibrozil is predicted to increase the steady-state apalutamide AUC and Cmax 44% and 32%, respectively.<sup>1</sup> For the active moieties (sum of unbound apalutamide plus the potency-adjusted unbound N-desmethyl apalutamide [an active metabolite]), the predicted steady-state AUC and Cmax increased 23% and 19%, respectively.<sup>1</sup><br><br>Apalutamide prescribing information states that no preemptive dose reduction of apalutamide is required when combined with strong CYP2C8 inhibitors.<sup>1</sup> Patients should be monitored for increased toxicities and dose reductions may be required based on tolerability.<sup>1</sup><br><br>The mechanism of this interaction is likely due to gemfibrozil-mediated inhibition of CYP2C8, an enzyme responsible for apalutamide metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Erleada (apalutamide) [prescribing information]. Horsham, PA: Janssen Products LP; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11965":"<p><b>Title</b> Apalutamide / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apalutamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased apalutamide toxicities when combined with strong CYP3A4 inhibitors. Apalutamide dose reductions may be required (to 180 mg or 120 mg daily) if toxicities occur.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the apalutamide prescribing information, itraconazole had no effect on the apalutamide (240 mg single dose) AUC and decreased the maximum serum concentration (Cmax) 22%.<sup>1</sup> Ketoconazole is predicted to increase the single dose apalutamide AUC 24% and increase the steady-state apalutamide AUC and Cmax 51% and 38%, respectively.<sup>1</sup> For the active moieties (sum of unbound apalutamide plus the potency-adjusted unbound N-desmethyl apalutamide [an active metabolite]), the predicted steady-state AUC and Cmax increased 28% and 23%, respectively.<sup>1</sup><br><br>Apalutamide prescribing information states that no preemptive dose reduction of apalutamide is required when combined with strong CYP3A4 inhibitors.<sup>1</sup> Patients should be monitored for increased toxicities and dose reductions may be required based on tolerability.<sup>1</sup><br><br>The mechanism of this interaction is likely due to ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for apalutamide metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Erleada (apalutamide) [prescribing information]. Horsham, PA: Janssen Products LP; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11966":"<p><b>Title</b> Apalutamide / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Apalutamide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased apalutamide efficacy if combined with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic modeling study described in the apalutamide prescribing information, rifampin is predicted to decrease the steady-state apalutamide AUC and maximum serum concentration (Cmax) 34% and 25%, respectively.<sup>1</sup> For the active moieties (sum of unbound apalutamide plus the potency-adjusted unbound N-desmethyl apalutamide [an active metabolite]), the predicted steady-state AUC and Cmax decreased 19% and 15%, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely due to rifampin-mediated induction of CYP3A4 and/or CYP2C8, enzymes responsible for apalutamide metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Erleada (apalutamide) [prescribing information]. Horsham, PA: Janssen Products LP; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11967":"<p><b>Title</b> Thyroid Products / Apalutamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Apalutamide may diminish the therapeutic effect of Thyroid Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor thyroid status closely in patients treated with thyroid products who initiate therapy with apalutamide. Increases in thyroid product doses may be required to maintain a euthyroid state.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> The apalutamide prescribing information states that hypothyroidism was reported for 8% of patients treated with apalutamide and 2% of patients treated with placebo, and elevated thyroid-stimulating hormone (TSH) concentrations occurred in 25% of patients treated with apalutamide and 7% of patients treated with placebo<sup>1</sup> Thyroid hormone replacement therapy may need to be initiated or require a dose increase upon initiation of apalutamide.<sup>1</sup><br><br>The mechanism of this interaction is unknown, but apalutamide induction of thyroid hormone metabolism may contribute.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Erleada (apalutamide) [prescribing information]. Horsham, PA: Janssen Products LP; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11968":"<p><b>Title</b> Rosuvastatin / Apalutamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Apalutamide may decrease the serum concentration of Rosuvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased rosuvastatin efficacy if combined with apalutamide. Rosuvastatin dose increases may be required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the apalutamide prescribing information, apalutamide decreased the rosuvastatin (single oral dose) AUC 41% and had no effect on the rosuvastatin maximum serum concentration.<sup>1</sup><br><br>Apalutamide prescribing information states that concomitant use of apalutamide with medications that are substrates BCRP or OATP1B1 (ie, rosuvastatin) may lead to decreased exposures of these substrates.<sup>1</sup> Patients should be monitored for loss of substrate efficacy if combined.<sup>1</sup> <br><br>The mechanism of this interaction has not been fully investigated, but apalutamide induction of BCRP and/or OATP1B1, transporters responsible for rosuvastatin disposition, may contribute.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Erleada (apalutamide) [prescribing information]. Horsham, PA: Janssen Products LP; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11969":"<p><b>Title</b> Fexofenadine / Apalutamide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Apalutamide may decrease the serum concentration of Fexofenadine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the apalutamide prescribing information, apalutamide decreased the fexofenadine (single oral dose) AUC 30% and had no effect on the fexofenadine maximum serum concentration.<sup>1</sup><br><br>Apalutamide prescribing information states that concomitant use of apalutamide with medications that are substrates of P-glycoprotein (P-gp) (ie, fexofenadine) may lead to decreased exposures of these substrates.<sup>1</sup> <br><br>The mechanism of this interaction has not been fully investigated, but apalutamide induction of P-gp, a transporter responsible for fexofenadine disposition, may contribute.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Erleada (apalutamide) [prescribing information]. Horsham, PA: Janssen Products LP; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11970":"<p><b>Title</b> Apixaban / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Apixaban. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients for increased apixaban effects/toxicities (eg, bleeding) if combined with clarithromycin. No apixaban dose adjustment is recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the apixaban prescribing information, clarithromycin (500 mg) increased the apixaban AUC and maximum serum concentration approximately 60% and 30%, respectively.<sup>1</sup> Additionally, a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with apixaban (14.11% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, rivaroxaban or dabigatran), concurrent use of erythromycin or clarithromycin was associated with a 40% decrease in the incidence rate ratio for major bleeding.<sup>2</sup> Use of other strong CYP3A4 inhibitors (ie, itraconazole, ketoconazole, posaconazole, or voriconazole) did not significantly increase the risk for major bleeding.<sup>2</sup> Of note, several other examined combinations in this cohort study yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>Although apixaban prescribing information recommends an apixaban dose adjustment when combined with strong inhibitors of CYP3A4 and P-glycoprotein, dose adjustment is not recommended when combined with clarithromycin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Eliquis (apixaban) [prescribing information]. New York, NY: Pfizer Inc; February 2018.</p>\n<p>2. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11971":"<p><b>Title</b> Dofetilide / Bictegravir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bictegravir may increase the serum concentration of Dofetilide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of dofetilide with bictegravir, emtricitabine, and tenofovir alafenamide is contraindicated.</p> \n<p><b>Discussion</b> The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information contraindicates use with dofetilide due to the potential for bictegravir to increase concentrations of dofetilide, potentially increasing the risk for serious adverse effects.<sup>1</sup> <br><br>Bictegravir appears to be an inhibitor of the transporters OCT2 and MATE1, increasing the AUC of metformin, which is a substrate for transporters, by an average of 39%.<sup>1</sup> The dofetilide prescribing information states that dofetilide should not be used with known inhibitors of renal cation transport,<sup>2</sup> though the specific transporters responsible for dofetilide transport are not identified.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p>2. Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Inc; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11972":"<p><b>Title</b> MetFORMIN / Bictegravir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bictegravir may increase the serum concentration of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Carefully consider the risks and benefits of concurrent use of metformin with bictegravir, emtricitabine, and tenofovir alafenamide, as the metformin effects and toxicity risks may be increased. Consider closer patient monitoring with use of this combination.</p> \n<p><b>Discussion</b> The metformin AUC was increased by an average of 39% with concurrent use of bictegravir and tenofovir alafenamide.<sup>1</sup> The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information recommends consideration of both the potential risks and benefits of combined use with metformin.<br><br>Bictegravir appears to be an inhibitor of the transporters OCT2 and MATE1, both of which are thought to be involved in the elimination of metformin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11973":"<p><b>Title</b> Bictegravir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of rifampin with bictegravir, emtricitabine, and tenofovir alafenamide is contraindicated.</p> \n<p><b>Discussion</b> The bictegravir AUC was decreased by an average of 75% with concurrent use of rifampin 600 mg/day in a study of healthy volunteers.<sup>1</sup> The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information contraindicates use with rifampin due to the substantial reduction in bictegravir exposure.<sup>1</sup><br><br>The likely mechanism for this apparent interaction is rifampin induction of the CYP3A- and/or UGT1A1-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11974":"<p><b>Title</b> Bictegravir / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When possible consider using an alternative anticonvulsant with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.</p> \n<p><b>Discussion</b> Specific data with the antiepileptic drugs carbamazepine, phenytoin, phenobarbital, and oxcarbazepine are not available, but the bictegravir AUC was decreased by an average of 75% with concurrent use of the strong CYP3A4 inducer and UGT1A1 inducer rifampin 600 mg/day in a study of healthy volunteers.<sup>1</sup> These antiepileptics are also strong or moderate inducers of CYP3A, and most of these are also known inducers of UGT1A1, suggesting a similar interaction could be expected. The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information states that the use of an alternative anticonvulsant should be considered.<br><br>The likely mechanism for this potential interaction is induction of the CYP3A- and UGT1A1-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11975":"<p><b>Title</b> Bictegravir / OXcarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When possible consider using an alternative anticonvulsant with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.</p> \n<p><b>Discussion</b> Specific data with the antiepileptic drugs carbamazepine, phenytoin, phenobarbital, and oxcarbazepine are not available, but the bictegravir AUC was decreased by an average of 75% with concurrent use of the strong CYP3A4 inducer and UGT1A1 inducer rifampin 600 mg/day in a study of healthy volunteers.<sup>1</sup> These antiepileptics are also strong or moderate inducers of CYP3A, and most of these are also known inducers of UGT1A1, suggesting a similar interaction could be expected. The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information states that the use of an alternative anticonvulsant should be considered.<br><br>The likely mechanism for this potential interaction is induction of the CYP3A- and UGT1A1-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11976":"<p><b>Title</b> Bictegravir / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When possible consider using an alternative anticonvulsant with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Specific data with the antiepileptic drugs carbamazepine, phenytoin, phenobarbital, and oxcarbazepine are not available, but the bictegravir AUC was decreased by an average of 75% with concurrent use of the strong CYP3A4 inducer and UGT1A1 inducer rifampin 600 mg/day in a study of healthy volunteers.<sup>1</sup> These antiepileptics are also strong or moderate inducers of CYP3A, and most of these are also known inducers of UGT1A1, suggesting a similar interaction could be expected. The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information states that the use of an alternative anticonvulsant should be considered.<br><br>The likely mechanism for this potential interaction is induction of the CYP3A- and UGT1A1-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11977":"<p><b>Title</b> Bictegravir / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When possible consider using an alternative anticonvulsant with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.</p> \n<p><b>Discussion</b> Specific data with the antiepileptic drugs carbamazepine, phenytoin, phenobarbital, and oxcarbazepine are not available, but the bictegravir AUC was decreased by an average of 75% with concurrent use of the strong CYP3A4 inducer and UGT1A1 inducer rifampin 600 mg/day in a study of healthy volunteers.<sup>1</sup> These antiepileptics are also strong or moderate inducers of CYP3A, and most of these are also known inducers of UGT1A1, suggesting a similar interaction could be expected. The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information states that the use of an alternative anticonvulsant should be considered.<br><br>The likely mechanism for this potential interaction is induction of the CYP3A- and UGT1A1-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11978":"<p><b>Title</b> Bictegravir / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of bictegravir, emtricitabine, and tenofovir alafenamide with St John's wort is not recommended.</p> \n<p><b>Discussion</b> Specific data with the moderate CYP3A4 inducer St John's wort is not available, but the bictegravir AUC was decreased by an average of 75% with concurrent use of the strong CYP3A4 inducer and UGT1A1 inducer rifampin 600 mg/day in a study of healthy volunteers.<sup>1</sup> The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information states that use with St John's wort is not recommended.<br><br>The likely mechanism for this apparent interaction is St John's wort induction of the CYP3A-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11979":"<p><b>Title</b> Bictegravir / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of bictegravir, emtricitabine, and tenofovir alafenamide with rifabutin or rifapentine is not recommended.</p> \n<p><b>Discussion</b> The bictegravir AUC and minimum serum concentraton were decreased by an average of 38% and 56%, respectively, with concurrent use of the moderate CYP3A4 inducer rifabutin 300 mg/day in a study of healthy volunteers.<sup>1</sup> The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information states that use with rifabutin or rifapentine is not recommended.<br><br>The likely mechanism for this apparent interaction is induction of the CYP3A- and/or UGT1A1-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11980":"<p><b>Title</b> Bictegravir / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of bictegravir, emtricitabine, and tenofovir alafenamide with rifabutin or rifapentine is not recommended.</p> \n<p><b>Discussion</b> The bictegravir AUC and minimum serum concentraton were decreased by an average of 38% and 56%, respectively, with concurrent use of the moderate CYP3A4 inducer rifabutin 300 mg/day in a study of healthy volunteers.<sup>1</sup> The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information states that use with rifabutin or rifapentine is not recommended.<br><br>The likely mechanism for this apparent interaction is induction of the CYP3A- and/or UGT1A1-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11981":"<p><b>Title</b> Bictegravir / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Regular coadministration of bictegravir, emtricitabine, and tenofovir alafenamide with or 2 hours after an aluminim-, magnesium-, or calcium-containing antacid is not recommended. Bictegravir, emtricitabine, and tenofovir alafenamide can be administered under fasting conditions at least 2 hours before antacids.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The bictegravir AUC was decreased by an average of 52% when administered 2 hours after a nonspecified maximum strength antacid (20 mL) under fasting conditions.<sup>1</sup> Similarly, the bictegravir AUC was decreased by an average of 47% and 79% when administered with a nonspecified maximum strength antacid (20 mL) under fed or fasting conditions, respectively.<sup>1</sup> When bictegravir was administered while fasting and 2 hours before the maximum strength antacid, the bictegravir AUC was decreased by only 13%.<sup>1</sup><br><br>The specific mechanism for this interaction is unspecified, but it appears more likely a chelation-type of interaction rather than pH-related. Cations such as iron, which do not increase gastric pH, also appear to interact in a similar manner.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11982":"<p><b>Title</b> Bictegravir / Calcium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is limited to orally administered calcium salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Salts may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Regular coadministration of bictegravir, emtricitabine, and tenofovir alafenamide under fasting conditions with or 2 hours after ingestion of a calcium salt is not recommended. Bictegravir, emtricitabine, and tenofovir alafenamide can be administered concurrently with a calcium salt under fed conditions.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n</div> \n<p><b>Discussion</b> The bictegravir AUC was decreased by an average of 33% when administered together with calcium carbonate (1200 mg) under fasting conditions, but when coadministered under fed conditions, the bictegravir AUC was not significantly altered.<sup>1</sup><br><br>The specific mechanism for this interaction is unspecified, but it appears more likely a chelation-type of interaction rather than pH-related. Cations such as iron, magnesium, and aluminum also appear to interact in at least a somewhat similar manner.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11983":"<p><b>Title</b> Bictegravir / Iron Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is limited to orally administered iron salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Regular coadministration of bictegravir, emtricitabine, and tenofovir alafenamide under fasting conditions with or 2 hours after ingestion of an iron salt is not recommended. Bictegravir, emtricitabine, and tenofovir alafenamide can be administered concurrently with an iron salt under fed conditions.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Carboxymaltose, Ferric Citrate, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Ferumoxytol, Iron Acetyltransferrin, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose, Polysaccharide-Iron Complex, Sodium Feredetate</p>\n</div> \n<p><b>Discussion</b> The bictegravir AUC was decreased by an average of 63% when administered together with ferrous fumarate (324 mg) under fasting conditions, but when coadministered under fed conditions, the bictegravir AUC was decreased by only 16%.<sup>1</sup><br><br>The specific mechanism for this interaction is unspecified, but it appears more likely a chelation-type of interaction rather than pH-related. Cations such as calcium, magnesium, and aluminum also appear to interact in at least a somewhat similar manner.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11984":"<p><b>Title</b> Bictegravir / Sucralfate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sucralfate may decrease the serum concentration of Bictegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Recommendations specific to sucralfate are not available in labeling, but based on recommendations for aluminum-containing antacids, bictegravir, emtricitabine, and tenofovir alafenamide can be administered under fasting conditions at least 2 hours before sucralfate. Regular coadministration of bictegravir, emtricitabine, and tenofovir alafenamide with or 2 hours after an aluminim-, magnesium-, or calcium-containing antacid is not recommended. Bictegravir, emtricitabine, and tenofovir alafenamide can be administered under fasting conditions at least 2 hours before antacids.</p> \n<p><b>Discussion</b> The bictegravir AUC was decreased by an average of 52% when administered 2 hours after a nonspecified maximum strength antacid (20 mL) under fasting conditions.<sup>1</sup> Similarly, the bictegravir AUC was decreased by an average of 47% and 79% when administered with a nonspecified maximum strength antacid (20 mL) under fed or fasting conditions, respectively.<sup>1</sup> When bictegravir was administered while fasting and 2 hours before the maximum strength antacid, the bictegravir AUC was decreased by only 13%.<sup>1</sup><br><br>The specific mechanism for this interaction is unspecified, but it appears more likely a chelation-type of interaction rather than pH-related. Cations such as iron, which do not increase gastric pH, also appear to interact in a similar manner.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11985":"<p><b>Title</b> Bictegravir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Bictegravir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of reduced bictegravir, emtricitabine, and tenofovir alafenamide effectiveness with concurrent use of any strong CYP3A4 inducers, and particularly those that are also inducers of UGT1A1. A complete list of UGT1A1 inducers is not available, but rifampin, carbamazepine, phenobarbital, and phenytoin all appear to be inducers of both CYP3A4 and UGT1A1. Rifampin is specifically contraindicated, and the use of carbamazepine, phenytoin, or phenobarbital is not recommended when alternatives are acceptable.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The bictegravir AUC was decreased by an average of 75% with concurrent use of rifampin 600 mg/day in a study of healthy volunteers.<sup>1</sup> Additionally, the bictegravir AUC was an average of 38% to 56% lower with the moderate CYP3A4 inducer rifabutin 300mg/day.<sup>1</sup> The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information states that strong inducers of both CYP3A4 and UGT1A1 could significantly reduce bictegravir concentrations.<sup>1</sup> Rifampin, carbamazepine, phenobarbital, and phenytoin all appear to be strong inducers of CYP3A4 and inducers of UGT1A1, but a complete assessment of which strong CYP3A4 inducers are also inducers of UGT1A1 is not available. The impact of CYP3A4 induction alone on bictegravir concentrations or effects is unclear.<br><br>The likely mechanism for this apparent interaction is induction of the CYP3A- and/or UGT1A1-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11986":"<p><b>Title</b> Bictegravir / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bictegravir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of adverse effects or toxicities related to bictegravir, emtricitabine, and tenofovir alafenamide effectiveness with concurrent use of any strong CYP3A4 inhibitors, and particularly those that are also inhibitors of UGT1A1. A complete list of UGT1A1 inhibitors is not available.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The bictegravir AUC was increased by an average of 61% with concurrent use of the strong CYP3A4 inhibitor voriconazole (300 mg twice daily) in a study of healthy volunteers.<sup>1</sup> The bictegravir, emtricitabine, and tenofovir alafenamide prescribing information states that strong inhibitors of CYP3A4 that are also inhibitors of UGT1A1 could significantly increase bictegravir concentrations.<sup>1</sup> Ketoconazole, atazanavir, and indinavir all appear to be strong inhibitors of CYP3A4 and inhibitors of UGT1A1, but a complete assessment of which strong CYP3A4 inhibitors are also inhibitors of UGT1A1 is not available. The impact of CYP3A4 inhibition alone on bictegravir concentrations or effects is unclear.<br><br>The likely mechanism for this apparent interaction is inhibition of the CYP3A- and/or UGT1A1-mediated metabolism of bictegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11994":"<p><b>Title</b> Dabigatran Etexilate / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased dabigatran efficacy (ie, thrombosis) if combined with phenobarbital.</p> \n<p><b>Discussion</b> In an observational study of 52 patients taking dabigatran for atrial fibrillation, one patient was also taking phenobarbital and phenytoin.<sup>1</sup> This patient’s trough dabigatran concentration was 9 mcg/L, which was more than 3 standard deviations below the mean dose-corrected trough concentrations of the cohort (70 mcg/L) and well below previously reported therapeutic trough concentrations of 30 to 130 mcg/L.<sup>1</sup> Additionally, a case report describes a 77-year-old woman taking phenobarbital who was started on dabigatran for atrial fibrillation.<sup>2</sup> After 3 months, she experienced a cardioembolic stroke. Although serum dabigatran concentrations were not obtained, it was presumed that she failed dabigatran therapy due to a drug interaction with phenobarbital.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated. Although P-glycoprotein (P-gp) induction by phenobarbital has been hypothesized, there is a lack of clinical evidence to support the claim that phenobarbital can induce P-gp.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chin PK, Wright DF, Zhang M, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. <i>Drugs R D</i>. 2014;14(2):113-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24797400\">[PubMed 24797400]</a></p>\n<p>2. King PK, Stump TA, Walkama AM, Ash BM, Bowling SM. Management of phenobarbital and apixaban interaction in recurrent cardioembolic stroke [published online February 1, 2018]. <i>Ann Pharmacother</i>. Doi: 10.1177/1060028018759938. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29457494\">[PubMed 29457494]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11995":"<p><b>Title</b> Dabigatran Etexilate / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased dabigatran efficacy (ie, thrombosis) if combined with primidone.</p> \n<p><b>Discussion</b> In an observational study of 52 patients taking dabigatran for atrial fibrillation, one patient was also taking phenobarbital (the active metabolite of primidone) and phenytoin.<sup>1</sup> This patient’s trough dabigatran concentration was 9 mcg/L, which was more than 3 standard deviations below the mean dose-corrected trough concentrations of the cohort (70 mcg/L) and well below previously reported therapeutic trough concentrations of 30-130 mcg/L.<sup>1</sup> Additionally, a case report describes a 77-year-old woman taking phenobarbital who was started on dabigatran for atrial fibrillation.<sup>2</sup> After 3 months, she experienced a cardioembolic stroke. Although serum dabigatran concentrations were not obtained, it was presumed that she failed dabigatran therapy due to a drug interaction with phenobarbital.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated. Although P-glycoprotein (P-gp) induction by phenobarbital has been hypothesized, there is a lack of clinical evidence to support the claim that phenobarbital can induce P-gp.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chin PK, Wright DF, Zhang M, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs R D. 2014;14(2):113-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24797400\">[PubMed 24797400]</a></p>\n<p>2. King PK, Stump TA, Walkama AM, Ash BM, Bowling SM. Management of phenobarbital and apixaban interaction in recurrent cardioembolic stroke [published online February 1, 2018]. <i>Ann Pharmacother</i>. doi: 10.1177/1060028018759938. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29457494\">[PubMed 29457494]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11996":"<p><b>Title</b> Isoniazid / Dolutegravir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: This interaction may only be of concern if dolutegravir and isoniazid are also combined with rifapentine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dolutegravir may enhance the adverse/toxic effect of Isoniazid. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for numerous adverse events, including flu-like symptoms (nausea, vomiting, fever, headache), orthostatic hypotension, and laboratory abnormalities (lymphopenia, elevated direct bilirubin, and elevated liver transaminases), if dolutegravir is combined with isoniazid.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, dolutegravir (50 mg daily) was combined with once weekly isoniazid (15 mg/kg, maximum 900 mg), once weekly rifapentine (900 mg) and pyridoxine (50 mg daily) for 3 weeks.<sup>1</sup> The study was terminated early, after the enrollment of just 4 subjects, due to severe adverse events that developed in 2 subjects (50%). Flu-like symptoms developed (eg, nausea, vomiting, fever, headache) 8 to 10 hours after the last doses of combination therapy and 1 subject required hospitalization for orthostatic hypotension.<sup>1</sup> Multiple laboratory abnormalities developed including lymphopenia, elevated direct bilirubin, and elevated liver transaminases (LFTs). Multiple mediators increased during the flu-like syndrome events, most notably interferon-gamma, but elevations in tumor necrosis factor alpha, C-reactive protein, and various chemokines and interleukins were also observed. It was noted that the 2 subjects who experienced adverse events were slow acetylators of isoniazid and their isoniazid AUC was 67% to 92% greater than historical controls.<sup>1</sup> All symptoms and laboratory abnormalities resolved 2 to 3 weeks after drug discontinuation.<sup>1</sup> In addition to these adverse events, the dolutegravir AUC and trough concentration decreased 46% and 74%, respectively.<sup>1</sup><br><br>The mechanism of this potential drug interaction and the reason for these adverse effects is unknown. It is also unclear if isoniazid, rifapentine, or the combination of agents is responsible for this interaction. The mechanism by which dolutegravir concentrations are reduced is also unknown, but rifapentine-mediated induction of UDP-glucuronosyltransferase (UGT) 1A1 or CYP3A4, enzymes responsible for dolutegravir metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brooks KM, George JM, Pau AK et al. Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine [published online February 3, 2018. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciy082. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29415190\">[PubMed 29415190]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11997":"<p><b>Title</b> Rifapentine / Dolutegravir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dolutegravir may enhance the adverse/toxic effect of Rifapentine. Rifapentine may decrease the serum concentration of Dolutegravir. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for numerous adverse events, including flu-like symptoms (nausea, vomiting, fever, headache), orthostatic hypotension, and laboratory abnormalities (lymphopenia, elevated direct bilirubin, and elevated liver transaminases), if dolutegravir is combined with rifapentine. Also monitor for decreased dolutegravir exposure and effects.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, dolutegravir (50 mg daily) was combined with once weekly isoniazid (15 mg/kg, maximum 900 mg), once weekly rifapentine (900 mg) and pyridoxine (50 mg daily) for 3 weeks.<sup>1</sup> The study was terminated early, after the enrollment of just 4 subjects, due to severe adverse events that developed in 2 subjects (50%). Flu-like symptoms developed (eg, nausea, vomiting, fever, headache) 8 to 10 hours after the last doses of combination therapy and 1 subject required hospitalization for orthostatic hypotension.<sup>1</sup> Multiple laboratory abnormalities developed including lymphopenia, elevated direct bilirubin, and elevated liver transaminases (LFTs). Multiple mediators increased during the flu-like syndrome events, most notably interferon-gamma, but elevations in tumor necrosis factor alpha, C-reactive protein, and various chemokines and interleukins were also observed. It was noted that the 2 subjects who experienced adverse events were slow acetylators of isoniazid and their isoniazid AUC was 67% to 92% greater than historical controls.<sup>1</sup> All symptoms and laboratory abnormalities resolved 2 to 3 weeks after drug discontinuation.<sup>1</sup> In addition to these adverse events, the dolutegravir AUC and trough concentration decreased 46% and 74%, respectively.<sup>1</sup><br><br>The mechanism of this potential drug interaction and the reason for these adverse effects is unknown. It is also unclear if isoniazid, rifapentine, or the combination of agents is responsible for this interaction. The mechanism by which dolutegravir concentrations are reduced is also unknown, but rifapentine-mediated induction of UDP-glucuronosyltransferase (UGT) 1A1 or CYP3A4, enzymes responsible for dolutegravir metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brooks KM, George JM, Pau AK et al. Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine [published online February 3, 2018. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciy082. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29415190\">[PubMed 29415190]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11998":"<p><b>Title</b> Benzhydrocodone / CYP2D6 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The significance of this interaction may be greater in patients who are also receiving a CYP3A4 inhibitor or with use of a strong CYP2D6 inhibitor that also inhibits CYP3A4.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Benzhydrocodone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of reduced analgesic response if using benzhydrocodone together with a strong CYP2D6 inhibitor. Patients using a CYP2D6 inhibitor that is also an inhibitor of CYP3A4 may experience greater hydrocodone concentrations and enhanced opioid effects.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In an observational study of patients receiving hydrocodone (the active moiety of the prodrug benzhydrocodone) (n=91), those who were also taking one or more CYP2D6 substrates or inhibitors had lower odds of experiencing what was defined as a clinically significant reduction in pain (at least a 13 mm decreased on a 100 mm visual analog scale measure of pain) (OR=0.33 (95% CI: 0.1 to 0.8)).<sup>1</sup> Similarly, hydrocodone recipients with a genetic lack of functional CYP2D6 (poor metabolizers or PMs) were shown to have more than 7-fold lower hydromorphone concentrations as compared to those with 2 wild-type copies of the gene encoding CYP2D6 in a cohort study of 156 women post-cesarean delivery, and according to the same study, only hydromorphone concentrations (and not hydrocodone concentrations) correlated significantly with pain relief.<sup>2</sup> The strong CYP2D6 inhibitor quinidine was shown to decrease the clearance of hydrocodone to hydromorphone such that their hydromorphone formation was similar to that of genetic PMs.<sup>3</sup><br><br>Conversely, the hydrocodone AUC and maximum serum concentration were not significantly changed when hydrocodone (20 mg single dose) was administered with the strong CYP2D6 inhibitor paroxetine (20 mg/day for 12 days).<sup>4</sup> In another study, the conversion of hydrocodone to hydromorphone was found to be of little or no significance in determining the response to hydrocodone, as measured by both pupil response and subjective ratings, with no significant differences among controls, individuals receiving the CYP2D6 inhibitor quinidine, and genetic PMs.<sup>5</sup> An animal study (in Rhesus monkeys) also found that inhibiting the conversion of hydrocodone to hydromorphone had no significant effect on overall hydrocodone effect.<sup>6</sup><br><br>Given these conflicting findings, the clinical importance of this apparent interaction remains uncertain. Labeling for single-entity hydrocodone products and benzhydrocodone products do not specifically caution about concurrent use of even strong CYP2D6 inhibitors, except regarding the use of both a CYP3A4 inhibitor and a CYP2D6 inhibitor.<sup>4,7,8</sup> The labeling for these products do contain strong warnings about the use of all CYP3A4 inhibitors, as CYP3A4 is primarily responsible for hydrocodone metabolism, mediating its N-demethylation to norhydrocodone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. <i>Acad Emerg Med</i>. 2014;21(8):879-885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25156930\">[PubMed 25156930]</a></p>\n<p>2. Stauble ME, Moore AW, Langman LJ, et al. Hydrocodone in postoperative personalized pain management: pro-drug or drug? <i>Clin Chim Acta</i>. 2014;429:26-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24269714\">[PubMed 24269714]</a></p>\n<p>3. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. <i>Clin Pharmacol Ther</i>. 1993;54(5):463-472. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7693389\">[PubMed 7693389]</a></p>\n<p>4. Hysingla (hydrocodone) [prescribing information]. Stamford, CT: Purdue Pharma L.P.; November 2014.</p>\n<p>5. Kaplan HL, Busto UE, Baylon GJ, et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. <i>J Pharmacol Exp Ther</i>. 1997;281(1):103-108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9103485\">[PubMed 9103485]</a></p>\n<p>6. Lelas S, Wegert S, Otton SV, Sellers EM, France CP. Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. <i>Drug Alcohol Depend</i>. 1999;54(3):239-249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10372797\">[PubMed 10372797]</a></p>\n<p>7. Zohydro ER (hydrocodone) [prescribing information]. San Diego, CA: Zogenix, Inc.; August 2014.</p>\n<p>8. Apadaz (benzhydrocodone and acetaminophen) [prescribing information]. Coralville, IA: KemPharm Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11999":"<p><b>Title</b> Benzhydrocodone / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients taking benzhydrocodone, monitor for decreased effects and withdrawal symptoms if a strong CYP3A4 inducer is initiated. Conversely, monitor patients for increased hydrocodone toxicities, including fatal respiratory depression, if a strong CYP3A4 inducer is discontinued. Consider benzhydrocodone dose adjustments until stable effects of the CYP3A4 inducer (either addition or removal) are achieved.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The prescribing information for benzhydrocodone warns that because CYP3A4 plays a major role in hydrocodone metabolism, CYP3A4 inducers may increase the metabolism of hydrocodone (the active moiety of the prodrug benzhydrocodone) and lead to decreased plasma concentrations.<sup>1</sup> Lack of efficacy, or development of a withdrawal syndrome could occur. The prescribing information also contains a boxed warning detailing that discontinuation of any CYP3A4 inducer in benzhydrocodone-treated patients could result in an increase in hydrocodone plasma concentrations. This may prolong adverse drug effects and potentially lead to fatal respiratory depression. Monitor patients closely who are taking or discontinuing CYP3A4 inducers, and consider benzhydrocodone dose adjustments until stable drug effects are achieved.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Apadaz (benzhydrocodone and acetaminophen) [prescribing information]. Coralville, IA: KemPharm Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}